Goodwin Biotechnology Inc. (GBI) disclosed recently that following its recent
formation, AREVA Med LLC has decided to extend its collaboration with GBI toward the development of AREVA
Med's lead-212 (212Pb) initiative to treat cancer. The operation previously engaged with AREVA will continue with
AREVA Med and will result in the manufacture of a new conjugated drug that will be radiolabeled by the NCI.
AREVA Med will benefit from the vast expertise in the nuclear industry from its parent company that allowed for the
production of this radioisotope previously considered a scarce resource.
David Fischer, EVP of GBI, said "We are pleased to learn of the expansion of AREVA's capabilities through the
formation of AREVA Med and we are honored to have been selected as AREVA Med's manufacturing partner for the
production of their new radiolabeled cancer treatment".
About Goodwin Biotechnology Inc.
GBI is one of the earliest contract manufacturing organizations (CMOs), established in 1992. GBI specializes in
process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical
studies and clinical trials. GBI's clients include small to midsized biotech companies throughout North America and
Europe. GBI's USA customers include universities, renowned cancer research institutes and various branches of the
U.S. government. GBI offers its clients the experience of an established US Contract Manufacturing Organization,
and provides services in a fully integrated offering, including process development, cell banking, GMP
manufacturing, conjugation, vialing, and distribution to the clinical trial sites. For more information visit www.goodwinbio.com
About AREVA Med LLC.
AREVA Med LLC is a subsidiary of AREVA with manufacturing facilities in 43 countries and a sales network in
more than 100 countries. AREVA offers customers reliable technological solutions for CO2-free power generation and
electricity transmission and distribution. AREVA is the world leader in nuclear power and the only company to cover
all industrial activities in this field. Our 75,000 employees are committed to continuous improvement on a daily basis,
making sustainable development the focal point of the group's industrial strategy. AREVA's businesses help meet the
21st century's greatest challenges: making energy available to all, protecting the planet, and acting responsibly
towards future generations. For more information visit www.areva.com
SOURCE: Goodwin Biotechnology Inc.